Cargando…
KRAS mutation in patients undergoing hepatic resection for colorectal liver metastasis: A biomarker of cancer biology or a byproduct of patient selection?
Autores principales: | Søreide, Kjetil, Sandvik, Oddvar M, Søreide, Jon A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wiley Periodicals, Inc
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288986/ https://www.ncbi.nlm.nih.gov/pubmed/25155780 http://dx.doi.org/10.1002/cncr.28979 |
Ejemplares similares
-
Time to halt perioperative chemotherapy for resectable colorectal liver metastasis?
por: Søreide, Kjetil
Publicado: (2021) -
Can molecular biomarkers replace a clinical risk score for resectable colorectal liver metastasis?
por: Veen, Torhild, et al.
Publicado: (2017) -
Assessment of clinically related outcomes and biomarker analysis for translational integration in colorectal cancer (ACROBATICC): study protocol for a population-based, consecutive cohort of surgically treated colorectal cancers and resected colorectal liver metastasis
por: Søreide, Kjetil, et al.
Publicado: (2016) -
Genetic and Epigenetic Traits as Biomarkers in Colorectal Cancer
por: Berg, Marianne, et al.
Publicado: (2011) -
Resection of asymptomatic primary tumour in unresectable stage IV colorectal cancer: time to move on from propensity matched scores to randomized controlled trials
por: Søreide, Kjetil
Publicado: (2016)